Should you bet on its revival?

Lupin has weathered some serious storms in the past. Losses, litigations, you name it. But hold up, they're not down for the count!

In FY24, Lupin's operating profit skyrocketed over three times, with the operating profit margin hitting 13%, the highest since FY18.

And the stock? It has been flexing hard, doubling up in the past year alone!

But rewind to 2018-19, and Lupin was feeling the heat. Its two giant acquisitions in the US, costing $880 million, turned duds as opioid-based painkillers faced severe flak.

This was followed by a severe revenue decline & heavy impairment charges. It had an exceptional loss (due to impairment) of nearly Rs 2,500 crore between FY18-FY20.

But the recent strength was set in motion in FY21 when it turned to its respiratory segment, launching its first-ever inhaler in the US that took off the same year.

Since then, Lupin has upgraded its game with non-oral complex generics (injectables & inhalers). It is eyeing to expand deeper into the US and European injectables markets.

Despite the glow-up, Lupin's history of missed swings is hard to shake off. Its R&D game? Kind of a hit-or-miss. To find out how, read our story from the link below.